NovaBay Pharmaceuticals 주식 주식분석 | 주식가격 | 뉴스 | NBY | US66987P2011 | A2ACBF

날짜	NovaBay Pharmaceuticals 주식 가격
	0.71 undefined
	0.73 undefined
	0.69 undefined
	0.71 undefined
	0.75 undefined
	0.74 undefined
	0.50 undefined
	0.51 undefined
	0.53 undefined
	0.49 undefined
	0.47 undefined
	0.47 undefined
	0.48 undefined
	0.46 undefined
	0.46 undefined
	0.45 undefined
	0.47 undefined
	0.48 undefined
	0.48 undefined

날짜	NovaBay Pharmaceuticals 매출	NovaBay Pharmaceuticals EBIT	NovaBay Pharmaceuticals 이익
2026e	16 백만 undefined	17,335.72 undefined	-1.88 백만 undefined
2025e	13.74 백만 undefined	-398,950 undefined	-3.65 백만 undefined
2024e	10.9 백만 undefined	-4.54 백만 undefined	-16.84 백만 undefined
2023	14.73 백만 undefined	-5 백만 undefined	-16.7 백만 undefined
2022	14.4 백만 undefined	-7.68 백만 undefined	-16.27 백만 undefined
2021	8.42 백만 undefined	-6.86 백만 undefined	-6.56 백만 undefined
2020	9.93 백만 undefined	-6.43 백만 undefined	-11.04 백만 undefined
2019	6.6 백만 undefined	-9.24 백만 undefined	-10.49 백만 undefined
2018	12.51 백만 undefined	-7.87 백만 undefined	-6.55 백만 undefined
2017	18.23 백만 undefined	-7.31 백만 undefined	-7.4 백만 undefined
2016	11.9 백만 undefined	-10.98 백만 undefined	-13.15 백만 undefined
2015	4.38 백만 undefined	-21.01 백만 undefined	-18.97 백만 undefined
2014	1.05 백만 undefined	-16.88 백만 undefined	-15.19 백만 undefined
2013	3.48 백만 undefined	-15.49 백만 undefined	-16.04 백만 undefined
2012	6.95 백만 undefined	-8.31 백만 undefined	-7.03 백만 undefined
2011	11.02 백만 undefined	-9.75 백만 undefined	-10.51 백만 undefined
2010	9.75 백만 undefined	-9.97 백만 undefined	-9.76 백만 undefined
2009	15.68 백만 undefined	2.74 백만 undefined	2.7 백만 undefined
2008	6.72 백만 undefined	-8.51 백만 undefined	-8.11 백만 undefined
2007	5.91 백만 undefined	-5.88 백만 undefined	-5.4 백만 undefined
2006	1.53 백만 undefined	-5.53 백만 undefined	-5.29 백만 undefined
2005	0 undefined	-3.57 백만 undefined	-3.46 백만 undefined
2004	0 undefined	-2.83 백만 undefined	-2.8 백만 undefined

	매출	EBIT	이익
2004	0 USD	-2.83 백만 USD	-2.8 백만 USD
2005	0 USD	-3.57 백만 USD	-3.46 백만 USD
2006	1.53 백만 USD	-5.53 백만 USD	-5.29 백만 USD
2007	5.91 백만 USD	-5.88 백만 USD	-5.4 백만 USD
2008	6.72 백만 USD	-8.51 백만 USD	-8.11 백만 USD
2009	15.68 백만 USD	2.74 백만 USD	2.7 백만 USD
2010	9.75 백만 USD	-9.97 백만 USD	-9.76 백만 USD
2011	11.02 백만 USD	-9.75 백만 USD	-10.51 백만 USD
2012	6.95 백만 USD	-8.31 백만 USD	-7.03 백만 USD
2013	3.48 백만 USD	-15.49 백만 USD	-16.04 백만 USD
2014	1.05 백만 USD	-16.88 백만 USD	-15.19 백만 USD
2015	4.38 백만 USD	-21.01 백만 USD	-18.97 백만 USD
2016	11.9 백만 USD	-10.98 백만 USD	-13.15 백만 USD
2017	18.23 백만 USD	-7.31 백만 USD	-7.4 백만 USD
2018	12.51 백만 USD	-7.87 백만 USD	-6.55 백만 USD
2019	6.6 백만 USD	-9.24 백만 USD	-10.49 백만 USD
2020	9.93 백만 USD	-6.43 백만 USD	-11.04 백만 USD
2021	8.42 백만 USD	-6.86 백만 USD	-6.56 백만 USD
2022	14.4 백만 USD	-7.68 백만 USD	-16.27 백만 USD
2023	14.73 백만 USD	-5 백만 USD	-16.7 백만 USD
2024e	10.9 백만 USD	-4.54 백만 USD	-16.84 백만 USD
2025e	13.74 백만 USD	-398,950 USD	-3.65 백만 USD
2026e	16 백만 USD	17,335.72 USD	-1.88 백만 USD

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

3.21	11.09	22.35	12.1	11.29	12.81	14.14	16.87	13.05	5.43	2.39	9.51	3.2	3.18	6.94	11.95	7.5	5.36	3.13
0	0	0	0	3.8	0.5	0	0.94	0.78	0.27	0.54	2.12	3.63	3.39	1.07	1.11	1.67	1.97	0.76
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0.02	0.23	0.52	1.35	0.87	0.5	0.28	0.49	0.61	3.22	3.44	2.88
0.08	0.23	0.42	0.41	0.51	0.45	0.42	0.45	0.72	0.73	0.26	1.97	1.66	1.76	0.89	0.57	0.77	0.56	0.39
3.29	11.32	22.77	12.51	15.6	13.76	14.56	18.28	14.78	6.95	4.54	14.47	8.99	8.61	9.39	14.24	13.16	11.33	7.15
0.27	0.55	1.15	1.46	1.81	1.59	1.27	0.89	0.72	0.44	0.4	0.37	0.47	0.2	1.36	0.52	0.6	1.95	1.38
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	2.28	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.53	0.35	0
0	0	0	0	110	170	140	60	140	150	160	540	610	550	480	480	480	490	497
0.27	0.55	1.15	1.46	1.92	1.76	1.41	0.95	0.86	0.59	0.56	0.91	1.08	0.75	1.84	1	10.81	5.07	1.88
3.56	11.87	23.92	13.97	17.52	15.52	15.97	19.23	15.64	7.54	5.1	15.38	10.07	9.36	11.23	15.24	23.97	16.4	9.03

0.23	0.25	0.21	0.22	0.23	0.23	0.29	0.37	0.45	0.52	0.04	0.15	0.15	0.17	0.28	0.42	1.16	3.62	2.06
10.82	14.62	32.59	33.72	37	38.47	42.39	54	64.44	72.88	85.39	110.62	113.51	119.76	125.72	147.96	150.9	165.08	176.1
-7.79	-13.07	-18.47	-26.59	-23.89	-28.2	-33.28	-40.31	-56.35	-71.55	-90.52	-103.67	-111.07	-114.98	-125.02	-136.06	-141.89	-158.15	-174.85
0	10	0	0	0	-10	-40	-10	-20	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.26	1.81	14.33	7.35	13.34	10.49	9.36	14.05	8.52	1.85	-5.09	7.1	2.59	4.95	0.98	12.32	10.17	10.55	3.31
0.14	0.37	0.14	0.41	0.27	0.41	0.47	0.46	1.67	1.87	2.48	0.46	0.47	0.55	0.33	0.3	1.05	1.08	1.13
0.17	0.52	1.14	1.17	1.23	0.73	1.06	1.34	1.62	1.06	1.98	1.8	1.67	0.97	2.71	1.8	1	1.37	1.07
0	2.5	3.04	2.5	2.17	1.49	1.31	1.38	0.34	0.43	0.17	2.07	2.84	2.32	0.04	0.73	1.29	1.81	0.95
0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.61	0	0.11	0	1.14
0	0	260	410	370	110	0	0	0	0	0	0	0	0	0	0	0	0	0
0.31	3.39	4.58	4.49	4.04	2.74	2.84	3.18	3.63	3.36	4.63	4.33	4.98	3.84	5.69	2.83	3.45	4.26	4.28
0	0	0.55	0.48	0.11	0	0	0	0	0	1.66	0	0	0	0	0	0	0	0
0	0	0	0	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	6.67	4.48	1.67	0	2.3	3.78	2.01	3.51	2.34	3.89	3.96	2.51	0.56	4.56	0.09	10.37	1.59	1.44
0	6.67	5.03	2.15	0.14	2.3	3.78	2.01	3.51	2.34	5.55	3.96	2.51	0.56	4.56	0.09	10.37	1.59	1.44
0.31	10.06	9.61	6.64	4.18	5.04	6.62	5.19	7.14	5.7	10.18	8.29	7.49	4.4	10.25	2.92	13.82	5.85	5.72
3.57	11.87	23.94	13.99	17.52	15.53	15.98	19.24	15.66	7.55	5.09	15.39	10.08	9.35	11.23	15.24	23.99	16.4	9.03

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-2	-3	-5	-5	-8	2	-4	-5	-7	-16	-15	-18	-13	-7	-6	-9	-11	-5	-10	-9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	9	-1	-3	-6	4	0	0	1	0	1	-2	-1	1	1	0	0	0	0
0	0	0	0	0	1	1	1	0	1	0	0	4	2	0	0	6	-3	2	4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-2	-3	4	-6	-9	-1	2	-3	-6	-12	-15	-18	-11	-6	-5	-7	-4	-9	-6	-4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1	-5	-5	10	-1	-1	-4	1	1	2	0	0	0	0	0	0	-12	0	0
0	-1	-5	-5	11	0	0	-4	1	1	2	0	0	0	0	0	0	-11	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	-1	0	0	2	-2	0	0	1
5	1	3	0	0	0	0	0	2	8	0	12	21	0	5	9	12	16	4	0
5	2	3	17	0	1	0	4	9	9	7	15	19	0	5	11	9	16	4	1
0	0	0	17	0	1	0	4	6	0	7	1	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	-1	2	6	1	-1	0	-3	4	-2	-5	-3	7	-6	0	3	5	-4	-2	-2
-2.7	-3.35	4.38	-6.93	-10.55	-2.38	1.83	-3.26	-6.68	-13.11	-15.13	-18.68	-11.82	-6.51	-5.61	-7.95	-4.75	-9.24	-6.76	-4.15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

NovaBay Pharmaceuticals 브루토마진	NovaBay Pharmaceuticals 이익 마진	NovaBay Pharmaceuticals EBIT-마진	NovaBay Pharmaceuticals 이익 마진
2026e	53.61 %	0.11 %	-11.73 %
2025e	53.61 %	-2.9 %	-26.61 %
2024e	53.61 %	-41.66 %	-154.54 %
2023	53.61 %	-33.97 %	-113.38 %
2022	54.03 %	-53.33 %	-112.99 %
2021	70.67 %	-81.47 %	-77.91 %
2020	60.02 %	-64.75 %	-111.18 %
2019	73.64 %	-140 %	-158.94 %
2018	88.01 %	-62.91 %	-52.36 %
2017	84.75 %	-40.1 %	-40.59 %
2016	79.24 %	-92.27 %	-110.5 %
2015	71.23 %	-479.68 %	-433.11 %
2014	54.29 %	-1,607.62 %	-1,446.67 %
2013	95.4 %	-445.11 %	-460.92 %
2012	-33.53 %	-119.57 %	-101.15 %
2011	53.61 %	-88.48 %	-95.37 %
2010	53.61 %	-102.26 %	-100.1 %
2009	53.61 %	17.47 %	17.22 %
2008	53.61 %	-126.64 %	-120.68 %
2007	53.61 %	-99.49 %	-91.37 %
2006	53.61 %	-361.44 %	-345.75 %
2005	53.61 %	0 %	0 %
2004	53.61 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2004	53.61 %	0 %	0 %
2005	53.61 %	0 %	0 %
2006	53.61 %	-361.44 %	-345.75 %
2007	53.61 %	-99.49 %	-91.37 %
2008	53.61 %	-126.64 %	-120.68 %
2009	53.61 %	17.47 %	17.22 %
2010	53.61 %	-102.26 %	-100.1 %
2011	53.61 %	-88.48 %	-95.37 %
2012	-33.53 %	-119.57 %	-101.15 %
2013	95.4 %	-445.11 %	-460.92 %
2014	54.29 %	-1,607.62 %	-1,446.67 %
2015	71.23 %	-479.68 %	-433.11 %
2016	79.24 %	-92.27 %	-110.5 %
2017	84.75 %	-40.1 %	-40.59 %
2018	88.01 %	-62.91 %	-52.36 %
2019	73.64 %	-140 %	-158.94 %
2020	60.02 %	-64.75 %	-111.18 %
2021	70.67 %	-81.47 %	-77.91 %
2022	54.03 %	-53.33 %	-112.99 %
2023	53.61 %	-33.97 %	-113.38 %
2024e	53.61 %	-41.66 %	-154.54 %
2025e	53.61 %	-2.9 %	-26.61 %
2026e	53.61 %	0.11 %	-11.73 %

날짜	NovaBay Pharmaceuticals 주당 매출	NovaBay Pharmaceuticals EBIT 당 주식	NovaBay Pharmaceuticals 주당 이익
2026e	3.27 undefined	0 undefined	-0.38 undefined
2025e	2.81 undefined	0 undefined	-0.75 undefined
2024e	2.23 undefined	0 undefined	-3.44 undefined
2023	122.29 undefined	-41.55 undefined	-138.66 undefined
2022	8.94 undefined	-4.77 undefined	-10.11 undefined
2021	6.74 undefined	-5.49 undefined	-5.25 undefined
2020	9.93 undefined	-6.43 undefined	-11.04 undefined
2019	10.65 undefined	-14.9 undefined	-16.92 undefined
2018	26.06 undefined	-16.4 undefined	-13.65 undefined
2017	41.43 undefined	-16.61 undefined	-16.82 undefined
2016	44.07 undefined	-40.67 undefined	-48.7 undefined
2015	54.75 undefined	-262.63 undefined	-237.13 undefined
2014	17.5 undefined	-281.33 undefined	-253.17 undefined
2013	87 undefined	-387.25 undefined	-401 undefined
2012	231.67 undefined	-277 undefined	-234.33 undefined
2011	367.33 undefined	-325 undefined	-350.33 undefined
2010	325 undefined	-332.33 undefined	-325.33 undefined
2009	522.67 undefined	91.33 undefined	90 undefined
2008	336 undefined	-425.5 undefined	-405.5 undefined
2007	591 undefined	-588 undefined	-540 undefined
2006	153 undefined	-553 undefined	-529 undefined
2005	0 undefined	-357 undefined	-346 undefined
2004	0 undefined	-283 undefined	-280 undefined

	주당 매출	EBIT 당 주식	주당 이익
2004	0 USD	-283 USD	-280 USD
2005	0 USD	-357 USD	-346 USD
2006	153 USD	-553 USD	-529 USD
2007	591 USD	-588 USD	-540 USD
2008	336 USD	-425.5 USD	-405.5 USD
2009	522.67 USD	91.33 USD	90 USD
2010	325 USD	-332.33 USD	-325.33 USD
2011	367.33 USD	-325 USD	-350.33 USD
2012	231.67 USD	-277 USD	-234.33 USD
2013	87 USD	-387.25 USD	-401 USD
2014	17.5 USD	-281.33 USD	-253.17 USD
2015	54.75 USD	-262.63 USD	-237.13 USD
2016	44.07 USD	-40.67 USD	-48.7 USD
2017	41.43 USD	-16.61 USD	-16.82 USD
2018	26.06 USD	-16.4 USD	-13.65 USD
2019	10.65 USD	-14.9 USD	-16.92 USD
2020	9.93 USD	-6.43 USD	-11.04 USD
2021	6.74 USD	-5.49 USD	-5.25 USD
2022	8.94 USD	-4.77 USD	-10.11 USD
2023	122.29 USD	-41.55 USD	-138.66 USD
2024e	2.23 USD	0 USD	-3.44 USD
2025e	2.81 USD	0 USD	-0.75 USD
2026e	3.27 USD	0 USD	-0.38 USD

Segmente	2014
Avenova Product	-
Product and Service, Other	-
Product	-
Technology Service	-
Wound Care	471,000 USD
Ophthalmology	329,000 USD
Other Segments	249,000 USD
Dermatology	5,000 USD

	Avenova Product	Product and Service, Other	Product	Technology Service	Wound Care	Ophthalmology	Other Segments	Dermatology
2014	0 USD	0 USD	0 USD	0 USD	471,000 USD	329,000 USD	249,000 USD	5,000 USD

	주식 수량
2004	10,000 Aktien
2005	10,000 Aktien
2006	10,000 Aktien
2007	10,000 Aktien
2008	20,000 Aktien
2009	30,000 Aktien
2010	30,000 Aktien
2011	30,000 Aktien
2012	30,000 Aktien
2013	40,000 Aktien
2014	60,000 Aktien
2015	80,000 Aktien
2016	270,000 Aktien
2017	440,000 Aktien
2018	480,000 Aktien
2019	620,000 Aktien
2020	1 백만 Aktien
2021	1.25 백만 Aktien
2022	1.61 백만 Aktien
2023	120,420 Aktien
2024e	120,420 Aktien
2025e	120,420 Aktien
2026e	120,420 Aktien

EPS-예상치	EPS-실제	보고 분기
-1.24	-1.37 (-10.73 %)	2024 Q2
-5.3	-5.25 (0.99 %)	2024 Q1
-10.61	-46.55 (-338.94 %)	2023 Q4
-0.41	-0.37 (9.2 %)	2023 Q3
-0.56	-0.64 (-14.16 %)	2023 Q2
-0.92	-0.85 (7.52 %)	2023 Q1
-0.17	-0.78 (-354.28 %)	2022 Q4
-1.24	-3.5 (-182.87 %)	2022 Q3
-1.24	-1.4 (-13.15 %)	2022 Q2
-1.06	-1.75 (-65.02 %)	2022 Q1
-1.77	-0.7 (60.4 %)	2021 Q4
-1.41	-1.75 (-23.76 %)	2021 Q3
-1.41	-1.4 (0.99 %)	2021 Q2
-1.41	-1.4 (0.99 %)	2021 Q1
-1.59	-1.4 (11.99 %)	2020 Q4
-1.41	-2.8 (-98.02 %)	2020 Q3
-1.94	-5.25 (-170.02 %)	2020 Q2
-2.47	-2.1 (15.13 %)	2020 Q1
-2.47	-4.55 (-83.88 %)	2019 Q4
-2.83	-0.35 (87.62 %)	2019 Q3
-2.47	-3.15 (-27.3 %)	2019 Q2
-4.07	-8.75 (-115.24 %)	2019 Q1
-2.95	-2.45 (16.83 %)	2018 Q4
-3.98	-3.15 (20.79 %)	2018 Q3
-4.24	-3.15 (25.74 %)	2018 Q2
-2.65	-4.55 (-71.61 %)	2018 Q1
-1.24	0.7 (156.57 %)	2017 Q4
-3.18	-5.6 (-76.02 %)	2017 Q3
-4.24	-3.85 (9.24 %)	2017 Q2
-4.07	-9.1 (-123.85 %)	2017 Q1
-2.47	-3.85 (-55.59 %)	2016 Q4
-5.66	-11.9 (-110.4 %)	2016 Q3
-10.61	-12.6 (-18.81 %)	2016 Q2
-23.86	-43.4 (-81.88 %)	2016 Q1
-48.08	-44.1 (8.27 %)	2015 Q4
-61.86	-61.25 (0.99 %)	2015 Q3
-61.86	-61.25 (0.99 %)	2015 Q2
-53.03	-78.75 (-48.51 %)	2015 Q1
-61.86	-78.75 (-27.3 %)	2014 Q4
-75.12	-70 (6.81 %)	2014 Q3
-79.54	-52.5 (33.99 %)	2014 Q2
-97.21	-70 (27.99 %)	2014 Q1
-66.28	-87.5 (-32.01 %)	2013 Q4
-88.38	-87.5 (0.99 %)	2013 Q3
-88.38	-96.25 (-8.91 %)	2013 Q2
-61.86	-96.25 (-55.59 %)	2013 Q1
-79.54	-61.25 (22.99 %)	2012 Q4
-35.35	0 (100 %)	2012 Q3
-70.7	-70 (0.99 %)	2012 Q2
-61.86	-78.75 (-27.3 %)	2012 Q1
-79.54	-8.75 (89 %)	2011 Q3
-83.96	17.5 (120.84 %)	2011 Q2
-44.19	-70 (-58.42 %)	2011 Q1
-22.09	8.75 (139.6 %)	2010 Q4
-66.28	-61.25 (7.59 %)	2010 Q3
-70.7	-43.75 (38.12 %)	2010 Q2
-67.76	-61.25 (9.6 %)	2010 Q1
-14.73	122.5 (931.52 %)	2009 Q4
-8.84	0 (100 %)	2009 Q3
-83.96	-8.75 (89.58 %)	2009 Q2
-79.54	-8.75 (89 %)	2009 Q1
-82.48	-61.25 (25.74 %)	2008 Q4
-119.31	-61.25 (48.66 %)	2008 Q3
-117.83	-96.25 (18.31 %)	2008 Q2
-61.86	-113.75 (-83.88 %)	2008 Q1
-61.86	-78.75 (-27.3 %)	2007 Q4

%-지분	이름	주식	변경
3.18043 %	Renaissance Technologies LLC	155,523	96,700
14.69873 %	Armistice Capital LLC	718,768	718,768
1.37949 %	Altium Capital Management LP	67,457	67,457
1.32569 %	Virtu Americas LLC	64,826	64,826
1.10429 %	Hudson Bay Capital Management LP	54,000	54,000
0.74973 %	Citadel Advisors LLC	36,662	-48,483
0.51249 %	Geode Capital Management, L.L.C.	25,061	0
0.34532 %	HRT Financial LP	16,886	-32,138
0.32632 %	Two Sigma Investments, LP	15,957	-11,716
0.28037 %	The Vanguard Group, Inc.	13,710	0
0.23182 %	Tower Research Capital LLC	11,336	149
0.17382 %	UBS Financial Services, Inc.	8,500	8,251
0.04861 %	Hall (Justin M)	2,377	0
0.03646 %	Freiman (Paul Edward)	1,783	0
0.03509 %	Wu (Mijia)	1,716	0
0.03509 %	Zheng (Jeff Yenyou)	1,716	0
0.03509 %	Sit (Swan)	1,716	0
0.01755 %	Zheng (Yongxiang)	858	0
0.00323 %	Morgan Stanley Smith Barney LLC	158	0
0.00176 %	Ventura Wealth Management	86	0
0.00176 %	BofA Global Research (US)	86	0
0.00172 %	American Portfolios Advisors, Inc	84	0
0.00102 %	Wells Fargo Bank, N.A.	50	21
0.00076 %	Osaic Holdings, Inc.	37	0
0.00076 %	Ronald Blue Trust, Inc.	37	0
0.00041 %	BlackRock Institutional Trust Company, N.A.	20	0
0.00031 %	RBC Dominion Securities, Inc.	15	0
0.00025 %	Northwestern Mutual Capital, LLC	12	12
0.00008 %	Marble Trail Advisors	4	0
0.00006 %	Advisory Services Network, LLC	3	3
0 %	Kunin (Audrey)	0	-5,961
0 %	Townsquare Capital, LLC	0	-1,533
0 %	Arete Wealth Advisors, LLC	0	-429
0 %	United Asset Strategies, Inc.	0	-311
0 %	Creative Planning, Inc.	0	-2,857
0 %	Feltz WealthPLAN, Inc.	0	-1
0 %	B. Riley Wealth Advisors, Inc.	0	-429
0 %	Jane Street Capital, L.L.C.	0	-563
0 %	Millennium Management LLC	0	-340
0 %	Bridgeway Capital Management, LLC	0	-4,429
0 %	Morgan Stanley & Co. LLC	0	-1
0 %	Northern Trust Investments, Inc.	0	-809
0 %	C2C Wealth Management, LLC	0	-571
0 %	Sugarloaf Wealth Management, LLC	0	-57
0 %	Garlikov (Julie)	0	-858

What values and corporate philosophy does NovaBay Pharmaceuticals represent?

NovaBay Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in developing and commercializing innovative therapies. The company is dedicated to providing advanced solutions in areas such as the treatment of infections and inflammation. NovaBay Pharmaceuticals Inc holds a strong commitment to improving patients' quality of life through their cutting-edge products and technologies. Their corporate philosophy revolves around fostering a culture of innovation, maintaining the highest standards of integrity, and delivering exceptional value to both patients and shareholders. As a result, NovaBay Pharmaceuticals Inc continues to make significant strides in the pharmaceutical industry by providing effective, reliable, and safe treatment options for a wide range of medical conditions.

In which countries and regions is NovaBay Pharmaceuticals primarily present?

NovaBay Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of non-antibiotic, anti-infective products. With its headquarters based in Emeryville, California, NovaBay Pharmaceuticals Inc has a strong presence and market recognition in the American biopharmaceutical industry. The company is dedicated to improving the lives of patients by addressing unmet medical needs, particularly in dermatology, ophthalmology, and wound care. NovaBay Pharmaceuticals Inc's innovative products and therapies have gained recognition from healthcare professionals and consumers alike, making it a prominent player in the United States.

What significant milestones has the company NovaBay Pharmaceuticals achieved?

NovaBay Pharmaceuticals Inc, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully developed a proprietary, FDA-cleared technology called Neutrox, which is used in various antimicrobial applications. Secondly, NovaBay Pharmaceuticals Inc obtained regulatory approvals for several of its products, including Avenova, a prescription eyelid and eyelash cleanser. Moreover, the company has successfully expanded its global presence by establishing partnerships and distribution agreements in different regions. Additionally, NovaBay Pharmaceuticals Inc has been consistently conducting clinical trials to explore the potential applications of its products in various medical fields. These achievements demonstrate the company's dedication to innovation and improving patient care.

What is the history and background of the company NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing non-antibiotic, antimicrobial products. Founded in 2000, NovaBay has been dedicated to providing innovative solutions for infectious diseases, particularly those caused by drug-resistant bacteria. With a focus on developing proprietary compounds based on its Aganocide® technology platform, the company aims to address unmet medical needs in various healthcare settings. NovaBay Pharmaceuticals has gained recognition for its research and development efforts aimed at treating conditions such as urinary catheter blockage and impetigo. The company has established a strong presence in the healthcare industry, leveraging its expertise to develop effective and safe antimicrobial products.

Who are the main competitors of NovaBay Pharmaceuticals in the market?

The main competitors of NovaBay Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc., and Abbott Laboratories.

In which industries is NovaBay Pharmaceuticals primarily active?

NovaBay Pharmaceuticals Inc is primarily active in the healthcare and pharmaceutical industries.

What is the business model of NovaBay Pharmaceuticals?

The business model of NovaBay Pharmaceuticals Inc is focused on developing and commercializing non-antibiotic anti-infective products for the healthcare industry. The company primarily operates in two segments: Avenova® for the domestic eye care market and CelleRx® for the global dermatology market. NovaBay's patented products aim to address unmet medical needs by providing innovative and effective solutions for treating infections without promoting antibiotic resistance. With a strategic focus on the ophthalmology and dermatology markets, NovaBay Pharmaceuticals Inc aims to enhance patient care and generate sustainable growth through its advanced non-antibiotic anti-infective products.

NovaBay Pharmaceuticals 2024의 P/E 비율은 얼마입니까?

NovaBay Pharmaceuticals의 P/E 비율은 -0.01입니다.

NovaBay Pharmaceuticals 2024의 KUV는 얼마입니까?

NovaBay Pharmaceuticals의 P/S 비율은 0.01입니다.

NovaBay Pharmaceuticals의 AlleAktien 품질 점수는 얼마인가요?

NovaBay Pharmaceuticals에 대한 AlleAktien 품질 점수는 4/10입니다.

NovaBay Pharmaceuticals 2024의 매출은 얼마인가요?

예상되는 NovaBay Pharmaceuticals 매출은 10.9 백만 USD입니다.

NovaBay Pharmaceuticals 2024의 이익은 얼마인가요?

예상되는 NovaBay Pharmaceuticals 이익은 -16.84 백만 USD입니다.

NovaBay Pharmaceuticals은 무엇을 하나요?

NovaBay Pharmaceuticals Inc is a biotechnology company that focuses on the development of antibiotics for the treatment of infectious diseases. The company has made a name for itself in various areas and is known for its innovative products. One important area of NovaBay Pharmaceuticals is ophthalmology. The company has developed the products Avenova and CelleRx, which are used for the treatment of eye infections. Avenova is a product for eye cleansing based on the basic-neutral hypochlorous acid formula. It helps reduce bacteria and has antiseptic properties. CelleRx is a solution used to combat infections of eye diseases and can help with the treatment of blepharitis and conjunctivitis. Another important area of NovaBay Pharmaceuticals is dermatology. Here, the company has launched the product NeutroPhase. This product is suitable for the treatment of skin infections and wounds. NeutroPhase contains the same basic-neutral hypochlorous acid formula as Avenova and has antiseptic and antibacterial properties. NovaBay Pharmaceuticals also deals with infectious diseases in animals and has developed the product Vetericyn. This solution is used for wound cleansing and the treatment of infections in pets. The business model of NovaBay Pharmaceuticals is based on the development of new, innovative products for the treatment of infectious diseases. In order to market its products, it works closely with doctors, pharmacists, and distribution partners. The company holds several patents and strives to sell its products worldwide. An important part of NovaBay Pharmaceuticals' business model is also collaborating with other companies in the healthcare sector. For example, the company has partnered with BioClin Therapeutics to jointly develop a new medication for the treatment of skin cancer. Conclusion: NovaBay Pharmaceuticals is a biotechnology company specializing in the development of new, innovative products for the treatment of infectious diseases. The company has made a name for itself in various areas and offers solutions for the treatment of eye, skin, and animal infections. The business model is based on close collaboration with other companies in the healthcare sector and the global sale of its products.

NovaBay Pharmaceuticals 배당금은 얼마입니까?

NovaBay Pharmaceuticals은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

NovaBay Pharmaceuticals이 얼마나 자주 배당을 지급하나요?

NovaBay Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

NovaBay Pharmaceuticals ISIN이 무엇입니까?

NovaBay Pharmaceuticals의 ISIN은 US66987P2011입니다.

NovaBay Pharmaceuticals WKN은 무엇인가요?

NovaBay Pharmaceuticals의 WKN은 A2ACBF입니다.

NovaBay Pharmaceuticals 티커는 무엇인가요?

NovaBay Pharmaceuticals의 티커는 NBY입니다.

NovaBay Pharmaceuticals이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 NovaBay Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 NovaBay Pharmaceuticals은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

NovaBay Pharmaceuticals의 배당 수익률은 얼마입니까?

NovaBay Pharmaceuticals의 현재 배당 수익률은 입니다.

NovaBay Pharmaceuticals의 배당금은 언제 지급되나요?

NovaBay Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

NovaBay Pharmaceuticals의 배당금은 얼마나 안전한가요?

NovaBay Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

NovaBay Pharmaceuticals의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

NovaBay Pharmaceuticals이(가) 속해 있는 섹터는 어디인가요?

NovaBay Pharmaceuticals은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von NovaBay Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

NovaBay Pharmaceuticals의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

NovaBay Pharmaceuticals의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

NovaBay Pharmaceuticals의 2023년도 배당금은 얼마였습니까?

2023년에 NovaBay Pharmaceuticals는 0 USD를 배당금으로 지급했습니다.

NovaBay Pharmaceuticals는 어떤 화폐로 배당금을 지급하나요?

NovaBay Pharmaceuticals의 배당금은 USD에 지급됩니다.

증권거래소	NovaBay Pharmaceuticals 티커
AMEX	NBY
뒤셀도르프	B9PA.DU
프랑크푸르트	B9PA.F
뮌헨	B9PA.MU

NovaBay Pharmaceuticals 티커	NovaBay Pharmaceuticals FIGI
NBYGBP:EP	BBG00PF1ZKY5
NBYGBP:EZ	BBG00PF1ZL00
NBYGBP:XS	BBG00PF1ZL19
NBYGBP:XJ	BBG00PF1ZL91
NBYGBP:E1	BBG00PF1ZLK8
NBYGBP:XQ	BBG00PF1ZLS0
NBYGBP:XX	BBG00PF1ZLT9
NBYGBP:XZ	BBG00PF1ZLV6
NBYEUR:XS	BBG00PG465K8
NBYEUR:XJ	BBG00PG465T9
NBYEUR:E1	BBG00PG46626
NBYEUR:XQ	BBG00PG46680
NBYEUR:XX	BBG00PG46699
NBYEUR:XZ	BBG00PG466B6
NBYEUR:EP	BBG00QJCPT68
NBYEUR:EZ	BBG00QJCPT86
NBYUSD:EP	BBG00VSV84L2
NBYUSD:EZ	BBG00VSV84N0
NBYUSD:XS	BBG00VSV84P8
NBYUSD:XJ	BBG00VSV84Y8
NBYUSD:E1	BBG00VSV8566
NBYUSD:XQ	BBG00VSV85F6
NBYUSD:XX	BBG00VSV85G5
NBYUSD:XZ	BBG00VSV85H4

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0	0	1	5	6	15	9	11	6	3	1	4	11	18	12	6	9	8	14	14	10	13	16
-	-	-	400.00	20.00	150.00	-40.00	22.22	-45.45	-50.00	-66.67	300.00	175.00	63.64	-33.33	-50.00	50.00	-11.11	75.00	-	-28.57	30.00	23.08
-	-	-	-	-	-	-	-	-33.33	100.00	-	75.00	81.82	83.33	91.67	66.67	55.56	62.50	50.00	50.00	-	-	-
0	0	0	0	0	0	0	0	-2	3	0	3	9	15	11	4	5	5	7	7	0	0	0
-2	-3	-5	-5	-8	2	-9	-9	-8	-15	-16	-21	-10	-7	-7	-9	-6	-6	-7	-5	-4	0	0
-	-	-500.00	-100.00	-133.33	13.33	-100.00	-81.82	-133.33	-500.00	-1,600.00	-525.00	-90.91	-38.89	-58.33	-150.00	-66.67	-75.00	-50.00	-35.71	-40.00	-	-
-2	-3	-5	-5	-8	2	-9	-10	-7	-16	-15	-18	-13	-7	-6	-10	-11	-6	-16	-16	-16	-3	-1
-	50.00	66.67	-	60.00	-125.00	-550.00	11.11	-30.00	128.57	-6.25	20.00	-27.78	-46.15	-14.29	66.67	10.00	-45.45	166.67	-	-	-81.25	-66.67
0.01	0.01	0.01	0.01	0.02	0.03	0.03	0.03	0.03	0.04	0.06	0.08	0.27	0.44	0.48	0.62	1	1.25	1.61	0.12	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커NBY

ISINUS66987P2011

WKNA2ACBF

NovaBay Pharmaceuticals 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

NovaBay Pharmaceuticals 주가 이력

NovaBay Pharmaceuticals 주식 매출, EBIT, 이익 US66987P2011 · A2ACBF

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

NovaBay Pharmaceuticals 매출, 이익 및 EBIT 역사

NovaBay Pharmaceuticals 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

NovaBay Pharmaceuticals 주식 마진 US66987P2011 · A2ACBF

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

NovaBay Pharmaceuticals 마진 역사

NovaBay Pharmaceuticals 주식 매출, EBIT, 주당 순이익 US66987P2011 · A2ACBF

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

NovaBay Pharmaceuticals 매출, 이익 및 EBIT 주당 역사

NovaBay Pharmaceuticals 주식 및 주식 분석

NovaBay Pharmaceuticals 매출 세분화 US66987P2011 · A2ACBF

세그먼트별 매출

세그먼트별 매출 개요

해석 및 사용

투자 전략

NovaBay Pharmaceuticals 매출 세분화

NovaBay Pharmaceuticals Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

NovaBay Pharmaceuticals 역사적인 P/E, EBIT 및 P/S에 따른 평가

NovaBay Pharmaceuticals 주식 수량 US66987P2011 · A2ACBF

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

NovaBay Pharmaceuticals 주식 분할

NovaBay Pharmaceuticals 수익 예상

NovaBay Pharmaceuticals 수익 놀라움

NovaBay Pharmaceuticals 주식 주주 구조

NovaBay Pharmaceuticals 임원진 및 경영진

NovaBay Pharmaceuticals 주식에 대한 자주 묻는 질문

What values and corporate philosophy does NovaBay Pharmaceuticals represent?

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
NBY

ISIN
US66987P2011

WKN
A2ACBF